WASHINGTON (AP) — The Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest indication of the Trump administration’s com… [1406 chars]
FDA plans ultra-fast review of three psychedelic drugs following Trump directive
RELATED ARTICLES
